Logo image of LGVN

LONGEVERON INC-A (LGVN) Stock Fundamental Analysis

NASDAQ:LGVN - Nasdaq - US54303L2034 - Common Stock - Currency: USD

1.56  -0.08 (-4.88%)

After market: 1.6592 +0.1 (+6.36%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to LGVN. LGVN was compared to 571 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for LGVN as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, LGVN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year LGVN has reported negative net income.
In the past year LGVN has reported a negative cash flow from operations.
LGVN had negative earnings in each of the past 5 years.
LGVN had a negative operating cash flow in each of the past 5 years.
LGVN Yearly Net Income VS EBIT VS OCF VS FCFLGVN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -5M -10M -15M -20M

1.2 Ratios

The Return On Assets of LGVN (-91.50%) is worse than 72.47% of its industry peers.
LGVN has a Return On Equity (-106.79%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -91.5%
ROE -106.79%
ROIC N/A
ROA(3y)-97.49%
ROA(5y)-72.14%
ROE(3y)-155.62%
ROE(5y)-144.72%
ROIC(3y)N/A
ROIC(5y)N/A
LGVN Yearly ROA, ROE, ROICLGVN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 -100 -200 -300

1.3 Margins

The Gross Margin of LGVN (73.06%) is better than 84.72% of its industry peers.
In the last couple of years the Gross Margin of LGVN has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for LGVN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 73.06%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.32%
GM growth 5Y-0.45%
LGVN Yearly Profit, Operating, Gross MarginsLGVN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K

More info and screens

7

2. Health

2.1 Basic Checks

LGVN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LGVN has more shares outstanding
Compared to 5 years ago, LGVN has more shares outstanding
LGVN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
LGVN Yearly Shares OutstandingLGVN Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 500K 1M 1.5M 2M 2.5M
LGVN Yearly Total Debt VS Total AssetsLGVN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

2.2 Solvency

LGVN has an Altman-Z score of -2.59. This is a bad value and indicates that LGVN is not financially healthy and even has some risk of bankruptcy.
LGVN's Altman-Z score of -2.59 is in line compared to the rest of the industry. LGVN outperforms 48.85% of its industry peers.
There is no outstanding debt for LGVN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.59
ROIC/WACCN/A
WACC9.44%
LGVN Yearly LT Debt VS Equity VS FCFLGVN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 10M -10M 20M 30M

2.3 Liquidity

LGVN has a Current Ratio of 7.67. This indicates that LGVN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 7.67, LGVN is in the better half of the industry, outperforming 71.40% of the companies in the same industry.
LGVN has a Quick Ratio of 7.67. This indicates that LGVN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 7.67, LGVN is in the better half of the industry, outperforming 71.58% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.67
Quick Ratio 7.67
LGVN Yearly Current Assets VS Current LiabilitesLGVN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 10M 20M 30M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 35.92% over the past year.
Looking at the last year, LGVN shows a very strong growth in Revenue. The Revenue has grown by 141.46%.
The Revenue for LGVN have been decreasing by -19.78% on average. This is quite bad
EPS 1Y (TTM)35.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.86%
Revenue 1Y (TTM)141.46%
Revenue growth 3Y-49.87%
Revenue growth 5Y-19.78%
Sales Q2Q%415.33%

3.2 Future

Based on estimates for the next years, LGVN will show a very strong growth in Earnings Per Share. The EPS will grow by 24.38% on average per year.
LGVN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 78.00% yearly.
EPS Next Y65.95%
EPS Next 2Y36.71%
EPS Next 3Y24.38%
EPS Next 5YN/A
Revenue Next Year165.46%
Revenue Next 2Y95.49%
Revenue Next 3Y78%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
LGVN Yearly Revenue VS EstimatesLGVN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 1M 2M 3M 4M 5M
LGVN Yearly EPS VS EstimatesLGVN Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 -2 -4 -6 -8 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LGVN. In the last year negative earnings were reported.
Also next year LGVN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LGVN Price Earnings VS Forward Price EarningsLGVN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LGVN Per share dataLGVN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

LGVN's earnings are expected to grow with 24.38% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.71%
EPS Next 3Y24.38%

More info and screens

0

5. Dividend

5.1 Amount

LGVN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LONGEVERON INC-A

NASDAQ:LGVN (2/21/2025, 8:00:02 PM)

After market: 1.6592 +0.1 (+6.36%)

1.56

-0.08 (-4.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)03-07 2025-03-07/amc
Inst Owners2.57%
Inst Owner Change85.05%
Ins Owners10.59%
Ins Owner Change-0.3%
Market Cap23.15M
Analysts82.22
Price Target9.05 (480.13%)
Short Float %4.88%
Short Ratio2.25
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-40.7%
Min EPS beat(2)-106.22%
Max EPS beat(2)24.81%
EPS beat(4)2
Avg EPS beat(4)-19.21%
Min EPS beat(4)-106.22%
Max EPS beat(4)24.81%
EPS beat(8)2
Avg EPS beat(8)-15.81%
EPS beat(12)4
Avg EPS beat(12)-9.22%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)39.14%
Min Revenue beat(2)-12.6%
Max Revenue beat(2)90.89%
Revenue beat(4)2
Avg Revenue beat(4)312.71%
Min Revenue beat(4)-70.59%
Max Revenue beat(4)1243.14%
Revenue beat(8)2
Avg Revenue beat(8)137.3%
Revenue beat(12)5
Avg Revenue beat(12)106.6%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)6.71%
EPS NQ rev (1m)0.48%
EPS NQ rev (3m)63.1%
EPS NY rev (1m)0%
EPS NY rev (3m)1.11%
Revenue NQ rev (1m)13.64%
Revenue NQ rev (3m)55.86%
Revenue NY rev (1m)0%
Revenue NY rev (3m)17.78%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.5
P/FCF N/A
P/OCF N/A
P/B 0.9
P/tB 0.99
EV/EBITDA N/A
EPS(TTM)-6.28
EYN/A
EPS(NY)-1.34
Fwd EYN/A
FCF(TTM)-1.05
FCFYN/A
OCF(TTM)-0.98
OCFYN/A
SpS0.12
BVpS1.73
TBVpS1.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -91.5%
ROE -106.79%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 73.06%
FCFM N/A
ROA(3y)-97.49%
ROA(5y)-72.14%
ROE(3y)-155.62%
ROE(5y)-144.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.32%
GM growth 5Y-0.45%
F-Score5
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 118.49%
Cap/Sales 60.91%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.67
Quick Ratio 7.67
Altman-Z -2.59
F-Score5
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)104.18%
Cap/Depr(5y)72.42%
Cap/Sales(3y)89.41%
Cap/Sales(5y)55.02%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)35.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.86%
EPS Next Y65.95%
EPS Next 2Y36.71%
EPS Next 3Y24.38%
EPS Next 5YN/A
Revenue 1Y (TTM)141.46%
Revenue growth 3Y-49.87%
Revenue growth 5Y-19.78%
Sales Q2Q%415.33%
Revenue Next Year165.46%
Revenue Next 2Y95.49%
Revenue Next 3Y78%
Revenue Next 5YN/A
EBIT growth 1Y15.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-5.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-11.98%
OCF growth 3YN/A
OCF growth 5YN/A